Silvant Capital Management’s NovoCure NVCR Stock Holding History

Silvant Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-3,560	Closed	-$270K	–	332
2022 Q3	$270K	Hold	3,560	–	–	0.02%	177
2022 Q2	$247K	Hold	3,560	–	–	0.06%	138
2022 Q1	$295K	Hold	3,560	–	–	0.06%	146
2021 Q4	$267K	Sell	3,560 -228	-6%	-$22.9K	0.05%	161
2021 Q3	$440K	Hold	3,788	–	–	0.08%	127
2021 Q2	$840K	Sell	3,788 -967	-20%	-$188K	0.13%	102
2021 Q1	$629K	Sell	4,755 -781	-14%	-$124K	0.11%	113
2020 Q4	$958K	Hold	5,536	–	–	0.16%	97
2020 Q3	$616K	Hold	5,536	–	–	0.12%	106
2020 Q2	$328K	Hold	5,536	–	–	0.06%	132
2020 Q1	$373K	Hold	5,536	–	–	0.08%	116
2019 Q4	$467K	Hold	5,536	–	–	0.09%	117
2019 Q3	$414K	Hold	5,536	–	–	0.08%	117
2019 Q2	$350K	Hold	5,536	–	–	0.06%	140
2019 Q1	$267K	Hold	5,536	–	–	0.05%	165
2018 Q4	$185K	Buy	5,536 +1,270	+30%	+$46.4K	0.04%	184
2018 Q3	$224K	Buy	+4,266	New	+$170K	0.03%	185

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Silvant Capital Management's NVCR Position: Q4 2022 in Review

Silvant Capital Management sold out of NovoCure (NVCR) in Q4 2022, closing a stake of 3,560 shares — an estimated $270K sold.

Silvant Capital Management first reported a position in NVCR in Q3 2018 and held it in 17 quarters. The position peaked at $958K in Q4 2020. 304 funds tracked by Wall St. Rank hold NVCR as of Q4 2022.

Silvant Capital Management reported no remaining NovoCure position as of Q4 2022 after selling out during the quarter.
Silvant Capital Management sold 3,560 NovoCure shares in Q4 2022, an estimated $270K.
Silvant Capital Management first reported a position in NovoCure in Q3 2018 and held it in 17 quarters.
Silvant Capital Management's NovoCure position peaked at $958K in Q4 2020.
304 funds tracked by Wall St. Rank held NovoCure as of Q4 2022.

Based on Silvant Capital Management's 13F filing for Q4 2022, filed 23 Jan 2023.